Get started
ACADIA Pharmaceuticals Inc.ACADIA Pharmaceuticals Inc.ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

ACAD chart


Full chart

ACAD upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪2.81 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
21.66
Basic EPS (TTM)
0.78 USD
Net income (FY)
‪−61.29 M‬ USD
Revenue (FY)
‪726.44 M‬ USD
Shares float
‪164.30 M‬
Beta (1Y)
0.86

Employees


Employees (FY)
598
Change (1Y)
+85 +16.57%
Revenue / Employee (1Y)
‪1.21 M‬ USD
Net income / Employee (1Y)
‪−102.48 K‬ USD

About ACADIA Pharmaceuticals Inc.


Sector
Health Technology
CEO
Catherine Owen Adams
Headquarters
San Diego
Website
acadia.com
Founded
1993
FIGI
BBG000BHG9K0
ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

ACAD news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of ACAD is 16.87 USD — it has increased by 0.84% in the past 24 hours. Watch ACADIA Pharmaceuticals Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange ACADIA Pharmaceuticals Inc. stocks are traded under the ticker ACAD.
ACAD stock has fallen by −2.26% compared to the previous week, the month change is a 3.82% rise, over the last year ACADIA Pharmaceuticals Inc. has showed a −42.93% decrease.
We've gathered analysts' opinions on ACADIA Pharmaceuticals Inc. future price: according to them, ACAD price has a max estimate of 39.00 USD and a min estimate of 11.00 USD. Watch ACAD chart and read a more detailed ACADIA Pharmaceuticals Inc. stock forecast: see what analysts think of ACADIA Pharmaceuticals Inc. and suggest that you do with its stocks.
ACAD reached its all-time high on Jul 7, 2020 with the price of 58.72 USD, and its all-time low was 0.65 USD and was reached on Nov 12, 2010. View more price dynamics on ACAD chart.
See other stocks reaching their highest and lowest prices.
ACAD stock is 4.38% volatile and has beta coefficient of 0.86. Track ACADIA Pharmaceuticals Inc. stock price on the chart and check out the list of the most volatile stocks — is ACADIA Pharmaceuticals Inc. there?
Today ACADIA Pharmaceuticals Inc. has the market capitalization of ‪2.81 B‬, it has decreased by −3.39% over the last week.
Yes, you can track ACADIA Pharmaceuticals Inc. financials in yearly and quarterly reports right on TradingView.
ACADIA Pharmaceuticals Inc. is going to release the next earnings report on Mar 3, 2025. Keep track of upcoming events with our Earnings Calendar.
ACAD earnings for the last quarter are 0.20 USD per share, whereas the estimation was 0.14 USD resulting in a 44.84% surprise. The estimated earnings for the next quarter are 0.22 USD per share. See more details about ACADIA Pharmaceuticals Inc. earnings.
ACADIA Pharmaceuticals Inc. revenue for the last quarter amounts to ‪250.40 M‬ USD, despite the estimated figure of ‪248.83 M‬ USD. In the next quarter, revenue is expected to reach ‪271.64 M‬ USD.
ACAD net income for the last quarter is ‪32.77 M‬ USD, while the quarter before that showed ‪33.39 M‬ USD of net income which accounts for −1.87% change. Track more ACADIA Pharmaceuticals Inc. financial stats to get the full picture.
No, ACAD doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 22, 2024, the company has 598.00 employees. See our rating of the largest employees — is ACADIA Pharmaceuticals Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ACADIA Pharmaceuticals Inc. EBITDA is ‪124.54 M‬ USD, and current EBITDA margin is −9.34%. See more stats in ACADIA Pharmaceuticals Inc. financial statements.
Like other stocks, ACAD shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ACADIA Pharmaceuticals Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ACADIA Pharmaceuticals Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ACADIA Pharmaceuticals Inc. stock shows the sell signal. See more of ACADIA Pharmaceuticals Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.